ClinicalTrials.gg
Not yet recruitingNCT06729645ACO/ARO/AIO-22Updated May 1, 2026

External Beam Radiotherapy Combined With Endorectal High-dose-rate Brachytherapy in Elderly and Frail Patients With Rectal Cancer

An interventional study of radiotherapy in Rectal Cancer, sponsored by University Hospital of Cologne. Not yet recruiting at 4 sites in Germany. Open to participants aged 70 Years and older. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by University Hospital of Cologne · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Not applicable
Ages
70 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 78 studies in Rectal Neoplasms with a site in Germany — 17 open to participants now, 27 under way, 4 of them phase 3. Rectal Neoplasms · Germany.

Planned enrollment
44th of 62
80 · median 124
Started
2026
with 2 others
No phase
11 of 78
5 open now
Primary completion
2031-09
later than 25 of 26 live
Registered
72nd of 78
by date

Among the 78 studies in Rectal Neoplasms with a site in Germany, this one is the 44th largest by planned enrollment of the 62 interventional ones that give a count, is one of 3 that started in 2026, is one of 11 with no phase, reaches primary completion later than 25 of the 26 other live ones, and was the 72nd registered.

Rectal Neoplasms

2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

17 of the 78 studies in Rectal Neoplasms with a site in Germany are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 70 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies in Rectal Neoplasms with a site in Germany, or all of them as a file.
02

Study summary

ACO/ARO/AIO-22 - External beam radiotherapy combined with endorectal high-dose-ratebrachytherapy in elderly and frail patients with rectal cancer.

A prospective multicentre trial of the German Rectal Cancer Study Group.

Read the detailed description

Epidemiological data indicate that more than 50% of patients with newly-diagnosed rectal cancer are older than 70 years, with rising numbers expected over the next decades. Albeit total mesorectal excision (TME) is considered part of the standard multimodal therapy in rectal cancer, elderly and frail rectal cancer patients are often unable to undergo radical surgery as the risk of surgical complications and postoperative mortality rises with increasing age and comorbidity. In an analysis of the Colorectal Cooperative Group UK (1988-200) in 34.194 patients with colorectal cancer, 21% of those aged over 85 years did not undergo operation, while the rates of no surgical intervention were 11% in the 75-84 years age group. Furthermore, these patients often receive no treatment at all due to frailty and concurrent diseases, resulting in local and/or systemic disease progression with associated symptoms and impaired quality of life (QoL).

Significant advances have been made in modern radiotherapy (RT), which can provide a valuable alternative non-operative treatment strategy for elderly and frail patients. Notably, to achieve clinical complete response (cCR) with RT alone, high doses are needed. Recent data from randomized trials (OPERA, MORPEUS) in young and fit patients with rectal cancer indicate that increased RT doses can be safely delivered following external beam (chemo)radiotherapy (EBRT) followed by endoluminal radiotherapeutic modalities, such as contact X-ray brachytherapy (CXB) or high-dose rate endorectal brachytherapy (HDR-BT). However, prospective studies testing this therapeutic concept in elderly and frail patients with rectal cancer remain limited. Also, despite the wide availability of brachytherapy, applicability of this concept remains largely unexplored in this challenging age subgroup in Germany.

The ACO/ARO/AIO-22 prospective trial will aim to evaluate the efficacy of EBRT in combination with endorectal HDR-BT to achieve local control (cCR) and maintain QoL in elderly and frail patients with rectal cancer that are considered unfit for radical surgery, but amenable to EBRT in combination with endorectal HDR-BT or CXB.

The ACO/ARO/AIO-22 incorporates several aspects that make this prospective study important:

  1. treatment decision making is challenging in elderly/frail patients with rectal cancer, whereas standardized treatment guidelines for this patient cohort are lacking, thus necessitating new clinical trials to establish the best possible treatment in this clinical setting;
  2. the combination of EBRT and HDR-BT has been shown to result in high rates of tumor response with almost 90% overall response and cCR rates of approximately 50-80%, especially in young and fit patients with early stage tumors, whereas prospective trials in elderly/frail patients remain limited;
  3. due to its very steep dose gradient, endorectal HDR-BT enables the delivery of a very high radiation dose to the tumor with a very steep decrease in the volume of normal tissue, thus increasing treatment efficacy while keeping toxicity low;
  4. albeit already tested in different countries such as France, the Netherlands and the UK, the concept of combining EBRT with endorectal HDR-BT has not been widely tested in Germany yet and, thus, a prospective study is needed to evaluate its efficacy and safety in elderly/frail patients with rectal cancer, to develop expertise and to make this modality widely available for this challenging patient cohort.

Altogether, the concept of combining EBRT with endorectal HDR-BT to be tested as part of the ACO/ARO/AIO-22 prospective trial constitutes an attractive option in elderly/frail patients with rectal cancer unfit for radical surgery as it can potentially provide long-term local control of the primary tumor, prevent disease-related morbidity, prolong survival, improve QoL and even lead to cCR with complete cure in selected cases.

03

Conditions studied

  • Rectal Cancer

Browse trials for

04

Who can participate

Ages eligible
70 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Elderly patients (age ≥70 years) with a G8-frailty score ≤ 14 based on the G8 geriatric assessment tool of frailty and/or elderly patients (age ≥70 years) with Physical Status (ASA PS) ≥ 3 and/ elderly patients (age ≥70 years) unsuitable to tolerate radical surgery as judged by the surgeon and/or elderly patients (age ≥70 years) that refuse radical surgery
  • ≥ 6 months
  • Male and female patients with confirmed diagnosis of rectal adenocarcinoma localized 0-16 cm from the anocutaneous line as measured by rigid rectoscopy
  • MRI-defined cT1-3d N0/+ M0, mrCRM - / +, \</= 2/3 involvement of the rectal wall circumference
  • Staging requirements: High-resolution, thin-sliced (i.e. 3mm) magnetic resonance imaging (MRI) of the pelvis is the mandatory local staging procedure.
  • Spiral-CT of the abdomen and chest to exclude distant .

Exclusion criteria

Exclusion Criteria:

  • Previous or current drug abuse
  • Other concomitant antineoplastic therapy
  • Prior or concurrent ≤ 3 years prior to enrolment in study (Exception: non-melanoma skin cancer or cervical carcinoma FIGO stage 0-

    1), unless the patient is continuously disease-free

  • Psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule (these conditions should be discussed with the patient before registration in the trial).
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Patients with Rectal cancer

    Patients will be initially treated with EBRT with 13 x 3 Gy to a total dose of 39 Gy to the primary tumor and pelvic lymph node, over a period of 2.5 weeks. Restaging with pelvic MRI and endoscopy will then be performed 6.5 weeks after completion of EBRT and prior to the first endorectal HDR-BT fraction to evaluate initial therapy response and the residual extent of the disease for target outlining. Following that, endorectal HDR-BT will be delivered with 3 x 8 Gy to a total dose of 24 Gy (dose prescription: 5 mm depth for cT1 tumors; 10 mm depth for cT2-3 tumors), with each endorectal brachytherapy application performed once weekly.

    Other: radiotherapy

Interventions

  • Otherradiotherapy

    External beam radiotherapy and endorectal brachytherapy

06

What researchers measure

Primary outcomes

  1. Rate of Clinical Complete Response (cCR) or Near cCR at 12 Months

    The primary efficacy endpoint is the proportion of patients achieving a clinical complete response (cCR) or near cCR at 12 months after the initiation of treatment, assessed through MRI and endoscopic evaluation. Quality of Life (QoL) at 12 Months Assessed using the EORTC QLQ-ELD14 questionnaire, tailored to evaluate the QoL in elderly cancer patients. The primary measure will be the change in the QoL score from baseline to 12 months.

    Time frame: 12 Months

Secondary outcomes

  1. Quality of Life and Functional Outcomes

    EORTC QLQ-C30 and QLQ-CR29 for general and colorectal cancer-specific QoL. Wexner-Score for anorectal function assessment. Sustained cCR at 2 Years Proportion of patients maintaining a cCR for two years post-treatment. Disease-Free Survival (DFS) at 2 Years Time from treatment initiation to recurrence or death from any cause. Cumulative Incidence of Locoregional Regrowth Frequency of locoregional tumor regrowth in patients who initially achieved cCR. Cumulative Incidence of Distant Metastases Occurrence of distant metastases within the two-year follow-up period. Overall Survival (OS) at 2 Years Duration from treatment initiation to death from any cause. Acute and Late Toxicity Evaluation Categorized based on NCI CTCAE v.5.0, focusing on adverse events related to treatment. G8 Geriatric Assessment Evaluation of frailty and health status using the G8 assessment tool, both at baseline and during follow-ups.

    Time frame: 2 years

Other outcomes

  1. Translational/Biomarker Studies

    Identification of molecular biomarkers predictive of treatment response or prognosis. Follow-Up Procedures Standardized Watch and Wait (W\&W) protocol for patients achieving cCR or near cCR at six months post-treatment.

    Time frame: 6 months

07

Study locations

4 sites
  • Klinikverbund Allgäu
    Kempten, BaBaden-Württembergs 87439, Germany
    • Florian f Sterzing, Prof. Dr. med. · Contact
  • Frankfurt Universitätsklinikum
    Frankfurt am Main, Hesse 60590, Germany
  • Klinik für Strahlentherapie, Cyberknife und Radioonkologie Universität zu Köln
    Cologne, North Rhine-Westphalia 50937, Germany
  • Leipzig, Universitätsklinikum
    Leipzig, Saxony 04103, Germany
    • Thomas t Kuhnt, Prof. Dr. · Contact+49 341 97-16650
08

References and documents

Publications

  • Fleischmann M, Diefenhardt M, Nicolas AM, Rodel F, Ghadimi M, Hofheinz RD, Greten FR, Rodel C, Fokas E; German Rectal Cancer Study Group. ACO/ARO/AIO-21 - Capecitabine-based chemoradiotherapy in combination with the IL-1 receptor antagonist anakinra for rectal cancer Patients: A phase I trial of the German rectal cancer study group. Clin Transl Radiat Oncol. 2022 Apr 6;34:99-106. doi: 10.1016/j.ctro.2022.04.003. eCollection 2022 May. PubMed 35449546 ↗
  • Dapper H, Fleischmann M, Tselis N, Diefenhardt M, Hofheinz RD, Weiss C, Grabenbauer GG, Merten R, Grosu AL, Kirste S, Rieken S, Classen J, Langer C, Kuhnt T, Schmidberger H, Ghadimi M, Giordano F, Nestle U, Koerber SA, Bock F, Geiger M, Polat B, Bruns CJ, Dieplinger G, Popp F, Zander T, Brunner T, Tribius S, Arnold D, Wurschi G, Piso P, Friede T, Horner-Rieber J, Gkika E, Rodel C, Fokas E; German Rectal Cancer Study Group. ACO/ARO/AIO-22 - External beam radiotherapy combined with endorectal high-dose-rate brachytherapy in elderly and frail patients with rectal cancer: A prospective multicentre trial of the German Rectal Cancer Study Group. Clin Transl Radiat Oncol. 2025 Apr 13;53:100958. doi: 10.1016/j.ctro.2025.100958. eCollection 2025 Jul. PubMed 40276115 ↗

Individual participant data

Plan to share: Yes

Supporting information: Study protocol

Access criteria: ACO/ARO/AIO-22

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Sep 2031, 60 months later.

Of 329 non-industry interventional studies with no phase under Rectal Neoplasms, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 78. This study's planned 60 months is above that.

Counting every sponsor, half of 336 studies reached it within 51 months; a quarter within 23 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2024
First posted
Dec 11, 2024
StartEst.
Sep 30, 2026
Primary completionEst.
Sep 30, 2031
CompletionEst.
Dec 30, 2031
Last update
May 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06729645
Lead sponsor
University Hospital of Cologne
Responsible party
Prof. Dr. med. Dr. Emmanouil Fokas (Prof Dr. med. Dr., University Hospital of Cologne) — Principal investigator
First posted
Dec 11, 2024
Start date
Sep 30, 2026 (estimated)
Primary completion
Sep 30, 2031 (estimated)
Completion
Dec 30, 2031 (estimated)
Last update
May 1, 2026

Study contacts

Emmanouil Fokas, MD DPhil
Contact
emmanouil.fokas@uk-koeln.de
+49 22147898710
Emmanouil Fokas, MD DPhil
Contact
+49 22147884763
Emmanouil Fokas, MD DPhil
study chair · University Hospital of Cologne

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion